Cargando…

DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

PURPOSE: In acute myeloid leukemia (AML), recurrent DNA methyltransferase 3A (DNMT3A) mutations are associated with chemoresistance and poor prognosis, especially in advanced-age patients. Gene-expression studies in DNMT3A-mutated cells identified signatures implicated in deregulated DNA damage resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Venugopal, Kartika, Feng, Yang, Nowialis, Pawel, Xu, Huanzhou, Shabashvili, Daniil E., Berntsen, Cassandra M., Kaur, Prabhjot, Krajcik, Kathryn I., Taragjini, Christina, Zaroogian, Zachary, Casellas Román, Heidi L., Posada, Luisa M., Gunaratne, Chamara, Li, Jianping, Dupéré-Richer, Daphné, Bennett, Richard L., Pondugula, Santhi, Riva, Alberto, Cogle, Christopher R., Opavsky, Rene, Law, Brian K., Bhaduri-McIntosh, Sumita, Kubicek, Stefan, Staber, Philipp B., Licht, Jonathan D., Bird, Jonathan E., Guryanova, Olga A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866212/
https://www.ncbi.nlm.nih.gov/pubmed/34716195
http://dx.doi.org/10.1158/1078-0432.CCR-21-2863
_version_ 1784655787276107776
author Venugopal, Kartika
Feng, Yang
Nowialis, Pawel
Xu, Huanzhou
Shabashvili, Daniil E.
Berntsen, Cassandra M.
Kaur, Prabhjot
Krajcik, Kathryn I.
Taragjini, Christina
Zaroogian, Zachary
Casellas Román, Heidi L.
Posada, Luisa M.
Gunaratne, Chamara
Li, Jianping
Dupéré-Richer, Daphné
Bennett, Richard L.
Pondugula, Santhi
Riva, Alberto
Cogle, Christopher R.
Opavsky, Rene
Law, Brian K.
Bhaduri-McIntosh, Sumita
Kubicek, Stefan
Staber, Philipp B.
Licht, Jonathan D.
Bird, Jonathan E.
Guryanova, Olga A.
author_facet Venugopal, Kartika
Feng, Yang
Nowialis, Pawel
Xu, Huanzhou
Shabashvili, Daniil E.
Berntsen, Cassandra M.
Kaur, Prabhjot
Krajcik, Kathryn I.
Taragjini, Christina
Zaroogian, Zachary
Casellas Román, Heidi L.
Posada, Luisa M.
Gunaratne, Chamara
Li, Jianping
Dupéré-Richer, Daphné
Bennett, Richard L.
Pondugula, Santhi
Riva, Alberto
Cogle, Christopher R.
Opavsky, Rene
Law, Brian K.
Bhaduri-McIntosh, Sumita
Kubicek, Stefan
Staber, Philipp B.
Licht, Jonathan D.
Bird, Jonathan E.
Guryanova, Olga A.
author_sort Venugopal, Kartika
collection PubMed
description PURPOSE: In acute myeloid leukemia (AML), recurrent DNA methyltransferase 3A (DNMT3A) mutations are associated with chemoresistance and poor prognosis, especially in advanced-age patients. Gene-expression studies in DNMT3A-mutated cells identified signatures implicated in deregulated DNA damage response and replication fork integrity, suggesting sensitivity to replication stress. Here, we tested whether pharmacologically induced replication fork stalling, such as with cytarabine, creates a therapeutic vulnerability in cells with DNMT3A(R882) mutations. EXPERIMENTAL DESIGN: Leukemia cell lines, genetic mouse models, and isogenic cells with and without DNMT3A(mut) were used to evaluate sensitivity to nucleoside analogues such as cytarabine in vitro and in vivo, followed by analysis of DNA damage and signaling, replication restart, and cell-cycle progression on treatment and after drug removal. Transcriptome profiling identified pathways deregulated by DNMT3A(mut) expression. RESULTS: We found increased sensitivity to pharmacologically induced replication stress in cells expressing DNMT3A(R882)-mutant, with persistent intra–S-phase checkpoint activation, impaired PARP1 recruitment, and elevated DNA damage, which was incompletely resolved after drug removal and carried through mitosis. Pulse-chase double-labeling experiments with EdU and BrdU after cytarabine washout demonstrated a higher rate of fork collapse in DNMT3A(mut)-expressing cells. RNA-seq studies supported deregulated cell-cycle progression and p53 activation, along with splicing, ribosome biogenesis, and metabolism. CONCLUSIONS: Together, our studies show that DNMT3A mutations underlie a defect in recovery from replication fork arrest with subsequent accumulation of unresolved DNA damage, which may have therapeutic tractability. These results demonstrate that, in addition to its role in epigenetic control, DNMT3A contributes to preserving genome integrity during replication stress. See related commentary by Viny, p. 573
format Online
Article
Text
id pubmed-8866212
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-88662122022-02-24 DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks Venugopal, Kartika Feng, Yang Nowialis, Pawel Xu, Huanzhou Shabashvili, Daniil E. Berntsen, Cassandra M. Kaur, Prabhjot Krajcik, Kathryn I. Taragjini, Christina Zaroogian, Zachary Casellas Román, Heidi L. Posada, Luisa M. Gunaratne, Chamara Li, Jianping Dupéré-Richer, Daphné Bennett, Richard L. Pondugula, Santhi Riva, Alberto Cogle, Christopher R. Opavsky, Rene Law, Brian K. Bhaduri-McIntosh, Sumita Kubicek, Stefan Staber, Philipp B. Licht, Jonathan D. Bird, Jonathan E. Guryanova, Olga A. Clin Cancer Res Translational Cancer Mechanisms and Therapy PURPOSE: In acute myeloid leukemia (AML), recurrent DNA methyltransferase 3A (DNMT3A) mutations are associated with chemoresistance and poor prognosis, especially in advanced-age patients. Gene-expression studies in DNMT3A-mutated cells identified signatures implicated in deregulated DNA damage response and replication fork integrity, suggesting sensitivity to replication stress. Here, we tested whether pharmacologically induced replication fork stalling, such as with cytarabine, creates a therapeutic vulnerability in cells with DNMT3A(R882) mutations. EXPERIMENTAL DESIGN: Leukemia cell lines, genetic mouse models, and isogenic cells with and without DNMT3A(mut) were used to evaluate sensitivity to nucleoside analogues such as cytarabine in vitro and in vivo, followed by analysis of DNA damage and signaling, replication restart, and cell-cycle progression on treatment and after drug removal. Transcriptome profiling identified pathways deregulated by DNMT3A(mut) expression. RESULTS: We found increased sensitivity to pharmacologically induced replication stress in cells expressing DNMT3A(R882)-mutant, with persistent intra–S-phase checkpoint activation, impaired PARP1 recruitment, and elevated DNA damage, which was incompletely resolved after drug removal and carried through mitosis. Pulse-chase double-labeling experiments with EdU and BrdU after cytarabine washout demonstrated a higher rate of fork collapse in DNMT3A(mut)-expressing cells. RNA-seq studies supported deregulated cell-cycle progression and p53 activation, along with splicing, ribosome biogenesis, and metabolism. CONCLUSIONS: Together, our studies show that DNMT3A mutations underlie a defect in recovery from replication fork arrest with subsequent accumulation of unresolved DNA damage, which may have therapeutic tractability. These results demonstrate that, in addition to its role in epigenetic control, DNMT3A contributes to preserving genome integrity during replication stress. See related commentary by Viny, p. 573 American Association for Cancer Research 2022-02-15 2021-10-28 /pmc/articles/PMC8866212/ /pubmed/34716195 http://dx.doi.org/10.1158/1078-0432.CCR-21-2863 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Translational Cancer Mechanisms and Therapy
Venugopal, Kartika
Feng, Yang
Nowialis, Pawel
Xu, Huanzhou
Shabashvili, Daniil E.
Berntsen, Cassandra M.
Kaur, Prabhjot
Krajcik, Kathryn I.
Taragjini, Christina
Zaroogian, Zachary
Casellas Román, Heidi L.
Posada, Luisa M.
Gunaratne, Chamara
Li, Jianping
Dupéré-Richer, Daphné
Bennett, Richard L.
Pondugula, Santhi
Riva, Alberto
Cogle, Christopher R.
Opavsky, Rene
Law, Brian K.
Bhaduri-McIntosh, Sumita
Kubicek, Stefan
Staber, Philipp B.
Licht, Jonathan D.
Bird, Jonathan E.
Guryanova, Olga A.
DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
title DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
title_full DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
title_fullStr DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
title_full_unstemmed DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
title_short DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
title_sort dnmt3a harboring leukemia-associated mutations directs sensitivity to dna damage at replication forks
topic Translational Cancer Mechanisms and Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866212/
https://www.ncbi.nlm.nih.gov/pubmed/34716195
http://dx.doi.org/10.1158/1078-0432.CCR-21-2863
work_keys_str_mv AT venugopalkartika dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT fengyang dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT nowialispawel dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT xuhuanzhou dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT shabashvilidaniile dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT berntsencassandram dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT kaurprabhjot dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT krajcikkathryni dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT taragjinichristina dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT zaroogianzachary dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT casellasromanheidil dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT posadaluisam dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT gunaratnechamara dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT lijianping dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT duperericherdaphne dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT bennettrichardl dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT pondugulasanthi dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT rivaalberto dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT coglechristopherr dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT opavskyrene dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT lawbriank dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT bhadurimcintoshsumita dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT kubicekstefan dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT staberphilippb dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT lichtjonathand dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT birdjonathane dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks
AT guryanovaolgaa dnmt3aharboringleukemiaassociatedmutationsdirectssensitivitytodnadamageatreplicationforks